Post-mortem spinal cords of ALS patients show higher immunoreactivity against PRMT1 as well as higher concentrations of ADMA in the cerebrospinal fluid compared to those of the control group [56], further supporting the relevance of PRMTs in disease progression. The gene discussed is PRMT1; the disease is amyotrophic lateral sclerosis.